Date published: 2026-9-5

1-800-457-3801

SCBT Portrait Logo
Seach Input

netrin-4 CRISPR/Cas9 KO Plasmid (h): sc-403229

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: human
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • netrin-4 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the netrin-4 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
  • Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: netrin-4 Antibody (A-7): sc-365280
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    netrin-4 CRISPR/Cas9 KO Plasmid (h)

    sc-403229
    20 µg
    $397.00

    Overview

    NTN4 encodes netrin-4, a secreted laminin-related guidance cue that modulates cell–matrix interactions and directional migration. Netrin-4 participates in axon pathfinding, vascular patterning, and tissue morphogenesis by influencing extracellular matrix organization and receptor-mediated signaling that shapes cytoskeletal dynamics. In endothelial and epithelial contexts, it can affect adhesion and barrier properties through cross-talk with integrin- and laminin-associated pathways. Dysregulated NTN4 expression or signaling has been linked to abnormal angiogenesis and invasive behavior in cancer and other disorders involving altered basement membrane remodeling.

    netrin-4 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the NTN4 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the NTN4 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the NTN4 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish netrin-4 protein expression.

    This CRISPR knockout system enables efficient generation of NTN4-deficient cell models for investigation of netrin-4 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting NTN4 exon(s) critical for netrin-4 function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple NTN4 genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by netrin-4 CRISPR/Cas9 KO Plasmid (h) and netrin-4 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the NTN4 locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by netrin-4 HDR Plasmid (h) and netrin-4 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by NTN4 homology arms to support homology-directed repair at defined NTN4 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.